FIGURE 1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

Antigens and antibody epitopes used in the CLIA. A, Schematic of EphA2 molecules. Wild-type EphA2 is an intact form that contains a transmembrane (TM) cytoplasmic domain. EphA2-NF is an N-terminal fragment released by MT1-MMP processing. EphA2-FL (full-length) is an extracellular form without the TM and cytoplasmic domains. Epitopes of the EphA2 antibodies are shown. SP, ligand-binding signal peptide; CR, cysteine-rich. B, Standard curves of EphA2-NF (circles) and EphA2-FL (squares) for the CLIA using mAbs against 76A1 and 62A1. The detection range of EphA2-NF was 10–10⁵ pg/mL, while the detection of EphA2-FL was negligible (squares).